13,218 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Avanza Fonder AB

Avanza Fonder AB purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,218 shares of the company’s stock, valued at approximately $1,804,000.

A number of other hedge funds also recently modified their holdings of NBIX. Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares in the last quarter. Truvestments Capital LLC bought a new stake in Neurocrine Biosciences in the third quarter valued at about $63,000. True Wealth Design LLC raised its position in Neurocrine Biosciences by 11,740.0% in the third quarter. True Wealth Design LLC now owns 592 shares of the company’s stock worth $68,000 after purchasing an additional 587 shares in the last quarter. Archer Investment Corp lifted its stake in Neurocrine Biosciences by 37.0% during the third quarter. Archer Investment Corp now owns 740 shares of the company’s stock worth $85,000 after purchasing an additional 200 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Neurocrine Biosciences during the third quarter valued at approximately $89,000. Institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares of the company’s stock, valued at $19,157,968. The trade was a 32.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,694 shares of company stock worth $9,676,730. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Up 0.9 %

NASDAQ:NBIX opened at $143.26 on Friday. The stock’s fifty day simple moving average is $131.84 and its 200-day simple moving average is $131.16. The firm has a market capitalization of $14.51 billion, a P/E ratio of 38.41 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98.

Wall Street Analyst Weigh In

NBIX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Piper Sandler reissued an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. BMO Capital Markets cut their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Finally, Barclays upped their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.81.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.